Formuepleje A/S
- SEC CIK
- 0001801212
- Latest filing
- Aug 27, 2026
CME holding history
CME Group Inc. in every 13F filed by Formuepleje A/S, including the quarters it was sold out or no filing was made. Changes compare share counts with the previous calendar quarter.
CME overviewAll 13F holders of CMEFull Q2 2026 holdings
- Shares (Q1 2022)
- 0
- Sold out in Q1 2022
- Value
- $0
- % of portfolio
- 0.0%
- Quarters held
- 28
- Since Q1 2014
| Quarter | Shares | Value | % of portfolio | Share change | Action | All holders |
|---|---|---|---|---|---|---|
| Q1 2022 | 0 | $0 | 0.0% | −100,600−100.0% | Sold out | Holders |
| Q4 2021 | 100,600 | $23.0M | 0.9% | −57,416−36.3% | Reduced | Holders |
| Q3 2021 | 158,016 | $30.6M | 1.2% | +227+0.1% | Added | Holders |
| Q2 2021 | 157,789 | $33.6M | 1.3% | −26,731−14.5% | Reduced | Holders |
| Q1 2021 | 184,520 | $37.7M | 1.4% | −8,333−4.3% | Reduced | Holders |
| Q4 2020 | 192,853 | $35.1M | 1.5% | −18,118−8.6% | Reduced | – |
| Q3 2020 | 210,971 | $35.3M | 1.5% | +56,247+36.4% | Added | – |
| Q2 2020 | 154,724 | $25.1M | 1.3% | +35,879+30.2% | Added | – |
| Q1 2020 | 118,845 | $20.5M | 1.4% | −67,468−36.2% | Reduced | – |
| Q4 2019 | 186,313 | $37.4M | 2.4% | +13,196+7.6% | Added | – |
| Q3 2019 | 173,117 | $36.6M | 2.7% | +1,982+1.2% | Added | – |
| Q2 2019 | 171,135 | $33.2M | 2.6% | +46,308+37.1% | Added | – |
| Q1 2019 | 124,827 | $20.5M | 1.8% | +124,827 | New | – |
| Q4 2018 | 0 | $0 | 0.0% | −143,156−100.0% | Sold out | – |
| Q3 2018 | 143,156 | $24.4M | 2.3% | 00.0% | Unchanged | – |
| Q2 2018 | 143,156 | $23.5M | 2.5% | +19,200+15.5% | Added | – |
| Q1 2018 | 123,956 | $20.0M | 2.4% | −28,800−18.9% | Reduced | – |
| Q4 2017 | 152,756 | $22.3M | 2.3% | +1,256+0.8% | Added | – |
| Q3 2017 | 151,500 | $20.6M | 2.3% | +151,500 | New | – |
| Q4 2016 | 0 | $0 | 0.0% | −71,219−100.0% | Sold out | – |
| Q3 2016 | 71,219 | $7.44M | 1.0% | −213,200−75.0% | Reduced | – |
| Q2 2016 | 284,419 | $27.7M | 3.8% | −204,550−41.8% | Reduced | – |
| Q1 2016 | 488,969 | $47.0M | 5.9% | −20,570−4.0% | Reduced | – |
| Q4 2015 | 509,539 | $46.2M | 5.3% | −400−0.1% | Reduced | – |
| Q3 2015 | 509,939 | $47.3M | 5.8% | −33,880−6.2% | Reduced | – |
| Q2 2015 | 543,819 | $50.6M | 6.0% | −2,830−0.5% | Reduced | – |
| Q1 2015 | 546,649 | $51.8M | 6.1% | −84,424−13.4% | Reduced | – |
| Q4 2014 | 631,073 | $55.9M | 7.1% | +55,840+9.7% | Added | – |
| Q3 2014 | 575,233 | $46.0M | 6.0% | −197,212−25.5% | Reduced | – |
| Q2 2014 | 772,445 | $54.8M | 5.5% | +579,875+301.1% | Added | – |
| Q1 2014 | 192,570 | $14.3M | 1.7% | – | – | – |
Livermore's 13F data starts with Q1 2014, so Q1 2014 has no change from the previous quarter.